DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Hida T, Nokihara H, Kondo M. et al.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet 2017;
390 (10/089) 29-39
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.